Chinese medical journal
-
Chinese medical journal · Feb 2024
Safety of teriflunomide in Chinese adult patients with relapsing multiple sclerosis: A phase IV, 24-week multicenter study.
Disease-modifying therapies have been approved for the treatment of relapsing multiple sclerosis (RMS). The present study aims to examine the safety of teriflunomide in Chinese patients with RMS. ⋯ NCT04410965, https://clinicaltrials.gov.